Lars Wallentin

Vitamin K antagonists in heart disease: Current status and perspectives (Section III)

Lars Wallentin, Felicita Andreotti, Colin Baigent et al. · Thrombosis and Haemostasis · 2013 · 354 citations

Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran

Michael D. Ezekowitz, Stuart J. Connolly, Amit Parekh et al. · American Heart Journal · 2009 · 333 citations

Thrombosis, Venous Thrombosis, Cardiovascular Disease +12

Dabigatran Versus Warfarin

Masatsugu Hori, Stuart J. Connolly, Jun Zhu et al. · Stroke · 2013 · 328 citations · Full text

Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study

Lars Lind, Lars Wallentin, Tibor Kempf et al. · European Heart Journal · 2009 · 235 citations

Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation

Michael D. Ezekowitz, Lars Wallentin, Stuart J. Connolly et al. · Circulation · 2010 · 169 citations